- Home
- AARD vs WQEY Comparison
AARD vs WQEY Comparison
Compare AARD & WQEY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$1.23
N/A
Current Price
$7.53
Company Overview
Basic Information| Metric | AARD | WQEY |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | British Virgin Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.4M | 108.2M |
| IPO Year | 2025 | 2026 |
Fundamental Metrics
Financial Performance| Metric | AARD | WQEY |
|---|---|---|
| Price | $1.23 | $7.53 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 45.9K |
| Earning Date | 11-16-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $67.35 |
| Revenue Next Year | N/A | $52.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.93 | $7.90 |
| 52 Week High | $16.60 | $10.25 |
Technical Indicators
Market Signals| Indicator | AARD | WQEY |
|---|---|---|
| Relative Strength Index (RSI) | 23.87 | 40.03 |
| Support Level | $0.93 | N/A |
| Resistance Level | $5.88 | $9.51 |
| Average True Range (ATR) | 0.44 | 0.78 |
| MACD | -0.20 | -0.13 |
| Stochastic Oscillator | 9.42 | 6.61 |
Price Performance
Historical Comparison AARD
WQEY
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.